Publications

CTD2 researchers at Dana Farber identify that 2-oxoglutarate dehydrogenase, a tricarboxylic acid cycle enzyme, is crucial to maintain PIK3CA mutant tumor survival or proliferation.

Scientists demonstrate that  Phosphoinositide 3-kinase enhancer (PIKE)-A directly interacts with CDK4. Furthermore, in vitro and in vivo studies in Glioblastoma (GBM) have shown that PIKE-A/CDK4 complex promotes cell proliferation and tumorigenesis. 

CTD2 investigators at UCSF developed an orthogonal CRISPR/Cas-approach to quantify loss- and gain-of-function phenotypes. This approach can be used to systematically identify genetic interactions between cancer relevant genes that can in turn illuminate the genome. 

Researchers developed a platform that integrates whole exome sequencing with high throughput drug screening in patient-derived tumor organoids. This platform has the potential to identify effective therapeutic strategies for patients where standard treatment options have been exhausted.

CTD2 scientists  at Emory University have identified Aurora Kinase A as a novel H-Ras binding partner in enhancing MAPK signaling. This novel protein-protein interaction is a potential therapeutic target in cancer.

CTD2 researchers at University of Texas Southwestern identify marine bacteria-derived natural product N⁶,N⁶-dimethyladenosine as a potent inhibitor of Akt signaling  in non-small cell lung cancer cell lines.